ADIL
Price
$4.22
Change
+$0.11 (+2.68%)
Updated
Oct 22 closing price
Capitalization
12.38M
21 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$92.33
Change
-$0.62 (-0.67%)
Updated
Oct 22 closing price
Capitalization
8.14B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADIL vs SYRE

ADIL vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
ADIL vs. SYRE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADIL is a StrongBuy and SYRE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADIL with price predictions
Oct 22, 2026

ADIL's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ADIL turned positive on October 20, 2026. Looking at past instances where ADIL's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADIL's RSI Indicator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ADIL as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +10.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADIL advanced for three days, in 157 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

ADIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

ADIL moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ADIL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ADIL entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ADIL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.323) is normal, around the industry mean (2.973). P/E Ratio (-0.238) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SYRE with price predictions
Oct 22, 2026

SYRE in upward trend: price rose above 50-day moving average on October 21, 2026

SYRE moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 68 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.

Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.527) is normal, around the industry mean (2.973). P/E Ratio (-48.104) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ADIL vs SYRE: Fundamental Ratings
ADIL
SYRE
OUTLOOK RATING
1..100
6425
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
9134
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for ADIL (39). This means that SYRE’s stock grew somewhat faster than ADIL’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ADIL (100). This means that SYRE’s stock grew similarly to ADIL’s over the last 12 months.

SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ADIL (100). This means that SYRE’s stock grew similarly to ADIL’s over the last 12 months.

SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ADIL (36). This means that SYRE’s stock grew similarly to ADIL’s over the last 12 months.

SYRE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for ADIL (91). This means that SYRE’s stock grew somewhat faster than ADIL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADILSYRE
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ADIL: $4.11 vs. SYRE: $92.95)
Brand notoriety: ADIL and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADIL: 42% vs. SYRE: 60%
Market capitalization -- ADIL: $12.38M vs. SYRE: $8.14B
ADIL [@Biotechnology] is valued at $12.38M. SYRE’s [@Biotechnology] market capitalization is $8.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADIL’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).

  • ADIL’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, SYRE is a better buy in the long-term than ADIL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADIL’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • ADIL’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ADIL and SYRE are a good buy in the short-term.

Price Growth

ADIL (@Biotechnology) experienced а +37.00% price change this week, while SYRE (@Biotechnology) price change was +18.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ADIL is expected to report earnings on Nov 12, 2026.

SYRE is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ADIL
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ADIL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADIL has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ADIL jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADIL
1D Price
Change %
ADIL100%
+2.68%
SYRE - ADIL
39%
Loosely correlated
-0.67%
VANI - ADIL
37%
Loosely correlated
-6.03%
VTVT - ADIL
29%
Poorly correlated
-2.20%
GDTC - ADIL
27%
Poorly correlated
+1.72%
AIM - ADIL
27%
Poorly correlated
-5.29%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.67%
ORKA - SYRE
51%
Loosely correlated
+1.54%
BEAM - SYRE
45%
Loosely correlated
-1.13%
IMVT - SYRE
44%
Loosely correlated
+2.54%
PMN - SYRE
44%
Loosely correlated
-5.26%
AVBP - SYRE
43%
Loosely correlated
+0.42%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EASY28.480.79
+2.86%
Liberty One Defensive Dividend Growth ETF (EASY)
FPRO23.810.23
+0.99%
Fidelity Real Estate Investment ETF (FPRO)
JHPI21.71N/A
N/A
John Hancock Preferred Income ETF (JHPI)
BBJP76.39-0.92
-1.19%
JPMorgan BetaBuilders Japan ETF (BBJP)
IGE65.10-1.15
-1.74%
iShares North American Natural Resources ETF (IGE)